Abstract
It is widely accepted that amyloidosis in Waldenström’s macroglobulinemia (WM) is exclusively due to amyloid light-chain deposition. However, only a small number of previous reports have actually characterized the type of amyloid in WM.We now report the third patient with WM and amyloid A protein (AA) amyloidosis. This patient developed malabsorption, nephrotic syndrome, and orthostatic hypotension. AA was immunohistochemically demonstrated in the rectal biopsy. In conjunction with previous examples of AA amyloidosis, the present report raises the possibility that AA amyloidosis may also occur in WM patients.
Similar content being viewed by others
References
Dimopoulos MA, Alexanian R. Waldenström’s macroglobulinemia.Blood. 1994;83:1452–1459.
Gillmore JD, Hawkins PN, Pepys MB. Amyloidosis: a review of recent diagnostic and therapeutic developments.Br J Haematol. 1997;99:245–256.
Urieli-Shoval S, Cohen P, Eisenberg S, Matzner Y. Widespread expression of serum amyloid A in histologically normal human tissues. Predominant localization to the epithelium.J Histochem Cytochem. 1998;46:1377–1384.
Orfila C, Rakotoarivony J, Segonds A, Suc JM. Immunofluorescence study of “non-idiopathic” renal amyloidosis.Hum Pathol. 1983;14:362–367.
Hirose H, Takemura Y, Honma S, et al. Nephrotic syndrome associated with generalized amyloidosis and IgM-monoclonal proteinemia.Jpn J Med. 1991;30:130–134.
Faa G, Van Eyken P, De Vos R, et al. Light chain deposition disease of the liver associated with AL-type amyloidosis and severe cholestasis.J Hepatol. 1991;12:75–82.
Julien J, Vital C, Vallat JM, et al. IgM demyelinative neuropathy with amyloidosis and biclonal gammopathy.Ann Neurol. 1984;15:395–399.
Gertz MA, Kyle RA, Noel P. Primary systemic amyloidosis: a rare complication of immunoglobulin M monoclonal gammopathies and Waldenström’s macroglobulinemia.J Clin Oncol. 1993;11:914–920.
Jones CH, Kanagasundaram NS, Coral AP, Coyne JD, Will EJ. Combined Waldenstrom’s macroglobulinaemia associated AL and beta-2-microglobulin amyloidosis.Nephrol Dial Transplant. 1997;12:2708–2712.
Zatloukal P, Bezdicek P, Schimonova M, Havlicek F, Tesarova P, Slovakova A. Waldenstrom’s macroglobulinemia with pulmonary amyloidosis.Respiration. 1998;65:414–416.
Strege RJ, Saeger W, Linke RP. Diagnosis and immunohistochemical classification of systemic amyloidoses. Report of 43 cases in an unselected autopsy series.Virchows Arch. 1998;433:19–27.
Møyner K, Sletten K, Husby G, Natvig JB. An unusually large (83 amino acid residues) amyloid fibril protein AA from a patient with Waldenström’s macroglobulinemia and amyloidosis.Scand J Immunol. 1980;11:549–554.
Ogami Y, Takasugi M, Soejima M. et al. Waldenstrom’s macroglobulinemia associated with amyloidosis and crescentic glomerulonephritis.Nephron. 1989;51:95–98.
Wright JR, Calkins E, Humphrey RL. Potassium permanganate reaction in amyloidosis. A histologic method to assist in differentiating forms of this disease.Lab Invest. 1977;36:274–281.
Ordi J, Grau JM, Junque A, Nomdedeu B, Palacin A, Cardesa A. Secondary (AA) amyloidosis associated with Castleman’s disease.Am J Clin Path. 1993;100:394–397.
Ikeda S, Chisuwa H, Kawasaki S, et al. Systemic reactive amyloidosis associated with Castleman’s disease: serial changes of the concentrations of acute phase serum amyloid A and interleukin 6 in serum.J Clin Pathol. 1997;50:965–967.
Husby G. Treatment of amyloidosis and the rheumatologist. State of the art and perspectives for the future.Scand J Rheumatol. 1998;7:161–165.
Yan SD, Zhu H, Zhu A, et al. Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis.Nature Med. 2000;6:643–651.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Gardyn, J., Schwartz, A., Gal, R. et al. Waldenström’s Macroglobulinemia Associated With AA Amyloidosis. Int J Hematol 74, 76–78 (2001). https://doi.org/10.1007/BF02982553
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF02982553